The problems and priorities involved in studying the role of conjugagive enzymes in developmental pharmacology are discussed and evaluated. The relative rates of UDP glucuronyltransfererase and P-glucuronidase were studied during perinatal development in hepatic and extrahepatic tissues to determine the net balance of glucuronidation or deglucuronidation at different developmental stages. In general, deglucuronidation predominated over glucuronidation in fetal tissues whereas the converse was evident in adults. 2,3,7,8-Tetrachlorodibenzop-dioxin I TCDD ), an extremely toxic contaminant of some organochlorine compounds, was shown to be a potent inducer of some hepatic and extrahepatic drug-metabolizing enzymes. TCDD, administered during gestation, induced the postnatal activities of p-nitrophenol glucuronyltransferase and benzpyrene hydroxylase in rats. Foster mother experiments revealed that the postnatal induction was caused primarily by newborn exposure to TCDD in the mother's milk. Tissue distribution experiments with TCDD-'4C confirmed these findings. Although TCDD induced nonsteroid glucuronidation, no significant effects were evident on the postnatal development of steroid glucuronidation. The synthetic estrogen diethylstilbestrol IDES Iis metabolized primarily by glucuronidation. The postnatal development of DES glucuronidation, like the steroid pathway, was not affected by gestational TCDD treatment. The fetal distribution of DES and DES-glucuronide, at different stages of development, correlated well with the perinatal development of steroid glucuronyltransferase activity.
Introduction
Many of the inherent problems in studying perinatal drug metabolism have been described previously (1) , and in general these apply to development aspects of conjugative enzymes as well.
On simplification, and depending on chemical structure, the drug biotransformation process may be separated into two parts: first an oxidative reaction, such as hydroxylation, results in the formation of a free hydroxyl group; this is then rapidly conjugated with glucuronic acid, sulfate, or another conjugate (2 a factors. For example, deconjugative reactions such as P-glucuronidase (3G) and aryl sulfatase perform the opposite reaction to form a less polar compound; liberating the free aglycone in the case of PG (3) . Like the mixed function oxidase (mfo) enzymes, many of the conjugative processes also play important roles in steroid metabolism as well as drug metabolism (4) . Glucuronides are often considered end products of metabolism, whereas sulfates play an integral role in steroidogenesis (5) , an area of obvious concern to the developmental toxicologist.
Some of the conjugative enzymes, most notable uridinediphosphoglucuronyltransferase, (UDP glucuronyltransferase, UDPGT), are microsomal and inducible by many of the same compounds that induce mfo enzymes, such as TCDD and phenobarbital (6) (7) (8) (9) . However, these enzymes are not P-450-dependent and some, such as the sulfotransferases, are located in the soluble fraction of mammalian cells (10) .
The first section of this paper will outline important objectives in studying the perinatal development of conjugative enzymes and this will be followed by recent research data related to these objectives. Most of the examples will involve UDPGT because of the available literature in developing systems, although other enzyme systems are also important. The sulfotransferases have been given relatively little attention because of the difficulty in obtaining sufficient quantities of phosphoadenosine phosphosulfate, the cofactor in sulfate transfer. This is now becoming commercially available, and sulfation will become a more easily studied process. NAcetyltransferase (NAT) functions in metabolism of some endogenous amines such as serotonin and the deactivation of many drugs (11) . Glycine conjugation is involved in the metabolism of some carbamate pesticides and functions in the heme biosynthetic pathway (2b). 
Animals
Like other biochemical processes, the activity of conjugative enzymes can vary tremendously depending on age, species, strain, time of day, and with exposure to other xenoboitics. In regards to mixed function oxidase activity, human fetal microsomes have significant activity, but experimental animals, at least noninduced animals, have low activities (12, 13) . In contrast, UDPGT has low activity in human fetal and kidney microsomes, whereas activity is quite high in the livers of the late fetuses of many experimental animals (8, 14) . These data constitute serious drawbacks in attempts to extrapolate data from experimental animals to the human condition. The low activity of most enzymes in fetal tissues often makes their measurement difficult. However the recent development of sensitive radiochemical procedures should help alleviate this problem (15, 16 As mentioned previously, the conjugative pathways play an important role in steroid metabolism as well as drug metabolism; especially sulfation and glucuronidation. There is considerable evidence supporting the idea that a different set of UDPGT conjugates steroids than nonsteroids (8, (17) (18) (19) . Although the evidence is not entirely conclusive, it is reasonable to assume that the developmental patterns, tissue distributions, and responses to inducing agents might be different for steroid conjugations compared to nonsteroid pathways.
Determine Developmental Patterns in Extrahepatic as Well as Hepatic Tissues
In recent years, increasing attention has been placed on the role of extrahepatic drug-metabolizing enzymes in fetuses as well as adults (20, 21) . The fetus has to be considered differently from adults, since foreign chemicals reach the fetus via the placenta whereas several routes of exposure are possible after birth. Also, fetal biotransformation capabilities differ markedly from those of mature animals (22) . Of course, the amount of parent compound or metabolites entering the fetus will vary depending on the mode of maternal exposure. It is important to determine the onset of conjugative activity in specific fetal tissues. This information should provide insight into how the fetus independently handles foreign chemicals at different developmental stages. We should also attempt to correlate these factors with susceptibility to transplacental toxicants. (23) (24) (25) (26) . The in vitro incubation conditions that most adequately reflect in vivo activities is a question which has not been adequately resolved. In addition, in vitro activation of fetal tissues might differ qualitatively or quantitatively from that of adult tissues, depending on the morphological localization of enzyme on the endoplasmic reticulum.
Conjugation and deconjugation reactions are of particular interest in the placenta, since the fetal-maternal transfer of some steroids is regulated by the net deconjugation rates (5) . This is particually true for the steroid sulfates. An area of recent concern to the NIEHS involves the identification of biochemical indicators that precede or accompany developmental toxicity. There is some evidence that the developmental pattern of conjugative enzyme pathways could relfect impending toxicity. This area is covered in detail in a separate article (27) .
What are the Factors that Regulate Onset of Conjugative Activity in the Fetus or Newborn?
This objective is of great importance to developmental toxicologists in relation to the factors that could delay or prematurely initiate onset of enzyme activity. Dutton's group in England has done considerable and elegant work on this subject (19) . They have used chick embryo liver cultures to study the developmental induction of glucuronyltransferase activity. Enzyme activity increases markedly in culture and actually exceeds that found normally in adult liver. Figure 1 illustrates the glucuronidation of a phenolic compound catalyzed by UDPGT. This process requires UDPGA as the cofactor and glucuronic acid donor. UDPGA synthesis is catalyzed by an NAD+-dependent UDPG dehydrogenase and is degraded by a nucleotide pyrophosphatase. However fetal UDPGA condentration is not the primary factor in regulating the onset of glucuronidation activity. The glucuronide product can also be degraded by PG, and high levels of this hydrolytic activity might be responsible for low fetal glucuronidation rates. However, this was also shown not to be the case, since PG inhibitors did not alter glucuronidation rates, and PG had only negligible activity at the pH used to measure glucuronidation. THe conclusion was that developmental onset of glucuronidation appears to be regulated by increased amounts of UDPGT (19, 28) . This idea was further reinforced by the ability of protein synthesis inhibitors to prevent the developmental onset of activity (29) . However, the situation is complicated by the fact that yolk added to the tissue culture delays the development of glucuronyltransferase (19) .
Perinatal Development of Glucuronyltransferase and P-Glucuronidase
The perinatal development of microsomal (-glucuronidase (PG) and UDP glucuronyltransferase (UDPGT) was investigated in rabbits, rats, and guinea pigs. Substrates used in these studies were p-nitrophenol (PNP) and p-nitrophenyl P-D-glucuronide. Results somes, since the patterns were similar for both microsomes and lysosomes. In liver, glucuronidation was first evident at day 38 of gestation, and activity gradually increased. The increase was dramatic near birth, so that for the first week after birth enzyme activity exceeded adult levels.
IG activity developed prior to UDPGT in liver and deconjugation exceeded conjugation until day 54 of gestation. Glucuronidation predominated at all subsequent developmental stages; the difference reaching a maximum of sevenfold by one week after birth and threefold in adults. In general, rats exhibited similar developmental patterns as guinea pigs but rabbits were different, in that no developmental peak in UDPGT activity about the time of birth was evident. Guinea pig lung exhibited a different developmental pattern than liver. UDPGT was not detec- birth some organochlorine compounds, most notably the herbicide 2,4,5-trichlorophenoxyacetic acid (33) . The oral LDso ranges from 1 Ag/kg in guinea pigs to 100 ,ug/kg in rats. We have also shown that TCDD is an extremely potent and persistent inducer of some microsomal enzymes in rats; approximately 50000 times more potent than the classic including agent phenobarbital (Table 1 , Fig. 7 ) (6). Induction is apparently caused by an increase in enzyme systheses as evidenced by kinetic data, UDPGT solubilization and partial purification studies, and the prevention of induction by actinomycin D (7).
TCDD, after administration to pregnant rats on day 5 of gestation, did not affect fetal glucuronidation rates of PNP (Fig. 8) . However, a marked postnatal inductive effect was observed. The increase was twofold 1 week after birth, and maximum induction (eightfold) occurred 3 weeks after birth. UDPGT activity 52 days after birth was still increased twofold. The developmental patterns were similar when pregnant rats were administered TCDD on the days 5, 10, or 16 of gestation. TCDD effects were also similar when PNP, 1-naphthol, or methylumbelliferone were used as substrates. Postnatal induction was evident in extrahepatic as well as hepatic tissues (Table 2) and occurred for hydroxylation reactions (8) .
The postnatal inductive effect must have resulted either from newborn exposure to TCDD in milk or to the activation of an inducing mechanism about the time of birth. Data from cross- Environmental Health Perspectives fostering experiments presented in Table 3 indicate that exposure of newborns to milk containing TCDD was the primary factor. Secretion of TCDD in milk appears to be an extremely efficient excretory system, since maternal induction levels decreased sharply postpartum after gastational TCDD treatment (Fig. 9) . If pups were removed from TCDD-treated mothers immediately after birth, preventing suckling, the maternal induction decay curve was less rapid. Induction levels in fetal and newborn tissues correlated well with tissue distribution experiments following treatment of pregnant rats with`4C-TCDD on the day 11 of gestation (J. Moore, NIEHS, unpublished observations). One day prior to birth, each fetus had received a dose of 0.3 jg/kg, whereas 14 days after birth the dose was 1.8
Mig/kg. Each fetus received approximately 1.0 ng TCDD by the day prior to birth, compared to 40 ng 14 days after birth. ' Pregnant rats were treated on the day 5 of gestation, and the newborns were sacrificed 8 days after birth.
I Group 1, control mothers nursing control pups; group 2, TCDD-treated mothers nursing TCDD-treated pups; group 3, TCDD-treated mothers nursing control pups; group 4, control mothers nursing prenatally TCDD-treated pups; group 5, mother rats administered TCDD immediately after giving birth.
Significantly different from group 1, p<O.Ol.
UDPGT Multiplicity
Considerable research has been documented recently to demonstrate the enzyme multiplicity of glucuronyltransferase (7,8 17-19) . Research in our laboratories has provided evidence that perinatal developmental patterns of steroid glucuronidations differ significantly from nonsteroid pathways (8) . Steroid The normal developmental patterns of steroid glucuronidations in control and TCDD-treated rats are illustrated in Figure 10 . The perinatal patterns differed from nonsteroid glucuronidations in two ways: (1) (35, 36) . It also appears that DES causes deficits in reproductive tract function and altered morphology in offspring following gestational exposures. Our studies were directed initially to determine whether DES is glucuronidated as a steroid or nonsteroid. The major metabolic pathway for DES is glucuronidation (37) , although some nonpolar metabolites have been identified (38) . The perinatal development in rats is illustrated on Figure 11 ; the data clearly indicate that DES is glucuronidated as a steroid. concentrations of DES remained relatively constant. Therefore, there were significantly greater fetal concentrations of radioactivity at the later stages compared to the earlier. This finding might have toxicological significance, in that DES-glucuronide should not be readily cleared from the fetal compartment and DES could be liberated from the fetal DES-glucuronide pool by/3G. DES was identified by Florisil chromatography and three thin-layer systems. Approximately 5% of the recovered radioactivity resided in unidentified nonpolar methabolites (32) . In a recent report (38) , several nonpolar metabolites of DES were identified in mammals, including dienstrol, hydroxyl, and methylated derivatives. It is possible that some of the unidentified compounds in mice (32) could be these metabolites. Metzler et al. (38) postulate that the dienstrol metabolites might be formed through an epoxide intermediate. It is concluded that the perinatal development of UDPGT plays an important role in the pharmacology and perhaps toxicity of many foreign chemicals. This enzyme system appears also to function in the metabolic regulation of steroid hormones during development and is sensitive to chemical insult in newborn as well as adult animals.
